Samia Salah

Samia Salah

Auto-generated profile, based on publicly available information

Samia Salah

Pediatric Rheumatology, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2014 in Lupus
Verified
Journal Article
Closed access
YLY A Lashine
Y A Lashine
SSS Salah
S Salah
HAH R Aboelenein
H R Aboelenein
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
MicroRNA-155 is involved in immune cell, differentiation, maturation and function. MiR-155 showed variable dysregulated expression in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. MiR-155 was previously confirmed to directly target CAMP response element binding protein (CREB), which was previously identified as a positive regulator of protein phosphatase 2A (PP2A). PP2A is a key negative regulator of interleukin-2, which is an important immune modulator and was previously shown to be decreased in SLE. In this study we aimed at investigating the regulation of PP2A by miR-155 and hence its role in juvenile SLE disease pathogenesis. MiR-155 showed significant downregulation in PBMCs from juvenile SLE and juvenile familial Mediterranean fever (FMF) and significant upregulation in PBMCs from juvenile idiopathic arthritis (JIA) patients. In SLE, miR-155 expression was negatively correlated with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score and proteinuria and was positively correlated with white blood cell (WBC) count. The mRNA of the catalytic subunit of PP2A (PP2Ac) showed significant upregulation in PBMCs from SLE and FMF but not in JIA patients. Additionally, the relative expression of PP2Ac mRNA was positively correlated with SLEDAI score. Forced expression of miR-155 led to decreased relative expression of PP2Ac mRNA and increased IL-2 release in cultured-stimulated PBMCs. This study suggests for the first time the possible role of an miR-155-PP2Ac loop in regulating IL-2 release and identifies miR-155 as a potential therapeutic target in juvenile SLE disease through relieving IL-2 from the inhibitory role of PP2A.

24 September 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AEAyman El-Garf
Ayman El-Garf
SSSamia Salah
Samia Salah
IIIman Iskander
Iman Iskander
HSHala Salah
Hala Salah
SASherif Naseh Amin
Sherif Naseh Amin

20 March 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SSSamia Salah
Samia Salah
HLHala Mohamed Lotfy
Hala Mohamed Lotfy
SSSamar M. Sabry
Samar M. Sabry
AHAzza El Hamshary
Azza El Hamshary
HTHeba Taher
Heba Taher

4 May 2017 in Growth Factors
Verified
Journal Article
Closed access
HAH. R. Aboelenein
H. R. Aboelenein
MHM. T. Hamza
M. T. Hamza
HMH. Marzouk
H. Marzouk
Rana A. YounessRana A. Youness
Rana A. Youness
MRM. Rahmoon
M. Rahmoon
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
MicroRNA-155 (miR-155) is implicated in regulating B-cell activation and survival that is important in systemic lupus erythematosus (SLE) pathogenesis. PU.1, a target for miR-155, is a crucial regulator of B-cell development and enhances Tumour-Necrosis-factor-alpha (TNF-α) expression. TNF-α induces the expression of B-cell-activating-factor (BAFF). BAFF is reported to increase the expression of the autoimmunity marker; CD19. This study aimed to investigate the regulation of expression of PU.1 in pediatric-systemic-lupus-erythematosus (pSLE) patients by miR-155, and hence evaluate its impact on TNF-α/BAFF/CD19 signalling pathway. Screening revealed that PU.1 is upregulated in PBMCs and B-cells of pSLE patients. PU.1 expression directly correlated with systemic-lupus-erythematosus disease-activity-index-2 K SLEDAI-2K. Ectopic expression of miR-155 and knockdown of PU.1 suppressed PU.1, TNF-α and BAFF. Finally, miR-155 decreased the proportion of BAFF-expressing-B-cells and CD19 protein expression. These findings suggest that miR-155 suppresses autoimmunity through transcriptional repression of PU.1 and TNF-α, which in turn suppresses BAFF and CD19 protein expression.

9 September 2014 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
SSSamia Salah
Samia Salah
SRSamia Rizk
Samia Rizk
HLHala M Lotfy
Hala M Lotfy
SHSalma EL Houchi
Salma EL Houchi
HMHuda Marzouk
Huda Marzouk
YFYomna Farag
Yomna Farag
Due to an increased frequency of vasculitis in FMF patients, many investigators have studied MEFV mutations in patients with HSP. The aim of the study is to investigate the frequency and clinical significance of MEFV mutations in Egyptian children with Henoch-Schonlein purpura (HSP). Investigating MEFV mutations in controls may help in estimating the prevalence of MEFV mutation carrier rate in Egyptian children. The study enrolled 90 individuals, sixty children with Henoch-Schonlein purpura (HSP), together with 30 sex-and age-matched apparently healthy controls. The entire study group was screened for 12 common MEFV mutations using a reverse hybridization assay of biotinylated PCR products. Patients with HSP had a significantly higher frequency of MEFV mutations (61.7%), when compared to the apparently healthy control population (36.7%). V726A was the most frequent mutation with an allelic frequency of 10.8%. Ninety- one percent of patients with MEFV mutations were heterozygous for one mutation, while 8.1% had a compound heterozygous MEFV gene mutations. The mutation V726A, followed by E148Q, were the leading mutations, present in 16.6% and in 13.3% of controls. MEFV mutations may be related to HSP susceptibility in children. The mutations were not associated with any clinical and laboratory manifestations. Screening for MEFV mutations in larger number of HSP children may be beneficial to evaluate any possible relationship between certain types of MEFV mutations and HSP, and compare the HSP MEFV mutations to the types of MEFV mutations associated with FMF.

19 April 2011
Verified
Journal Article
Closed access
YLY A Lashine
Y A Lashine
ASA M Seoudi
A M Seoudi
SSSamia Salah
Samia Salah
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz